Clinical trials: Dermatologic Diseases
Systemic Lupus Erythematosus (SLE), Systemic Sclerosis (SSc)
A Clinical Study of YTS109 Cell in R/R Autoimmune Diseases
This study evaluates the safety and efficacy of YTS109 cells in adults with relapsed/refractory autoimmune diseases, such as Systemic Lupus Erythematosus (SLE), Systemic Sclerosis (SSc), etc.
- Conditions
- Systemic Lupus Erythematosus (SLE), Systemic Sclerosis (SSc), Inflammatory Myopathy, Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis
- Trial name
- NCT06978647
- Testing
- YTS109 cell
- Where
- China
- Volunteers
- 12 people
- Sponsor
- China Immunotech (Beijing) Biotechnology Co., Ltd.
Advanced or Metastatic Solid Tumors, Breast Cancer
A Phase 1/2 Study of VIO-01 in Participants With Recurrent Solid Tumors
The goal of this phase 1/2 clinical trial is to investigate the safety of an investigational drug called VIO-01 when taken by people who have different types of solid tumor cancers.
- Conditions
- Advanced or Metastatic Solid Tumors, Breast Cancer, Recurrent Ovarian Cancer, Prostate Cancer
- Trial name
- NCT06257758
- Testing
- VIO-01
- Where
- 3 sites in United States
- Volunteers
- 6 people
- Sponsor
- Valerio Therapeutics
Hair Thinning
Study Evaluating Xtressé Gummy Supplement in Women With Self-Perceived Thinning Hair
The goal of this study is to determine how safe and effective it is to improve hair growth using an active gummy treatment in women with self-perceived thinning hair. The main aims of this trial are: 1.
- Trial name
- NCT07224555
- Testing
- Xtressé Hair Growth Gummies
- Where
- 4 sites in United States
- Volunteers
- 60 people
- Sponsor
- Restore Biologics Holdings, Inc. dba Xtressé
Acne Vulgaris
Sebacia Postmarket Study of Real-World Use
Postmarket study of Sebacia Microparticles treatment during adoption into clinical use for patients with mild to moderate inflammatory acne vulgaris.
- Trial name
- NCT03818555
- Testing
- Sebacia Microparticles Treatment
- Where
- 6 sites in United States
- Volunteers
- 125 people
- Sponsor
- Sebacia, Inc.
Herpes Genitalis
A Clinical Research Study For The Suppression And Treatment Of Genital Herpes Infection In HIV-Infected Persons
This clinical research study will be an international trial evaluating the safety and effectiveness of a marketed drug compared to placebo (like a sugar pill) for the suppression of repeated genital herpes infections in…
- Trial name
- NCT00079911
- Testing
- valacyclovir hydrochloride
- Where
- 5 sites in United States, Australia and 1 more
- Volunteers
- 7 people
- Sponsor
- GlaxoSmithKline
Skin Texture Disorder, Photoaging
Safety and Efficacy Evaluation of the Mosaic Ultra Device
Evaluate the Safety and Efficacy of the Mosaic Ultra 1550nm system for the treatment of skin tone and texture, facial rejuvenation, photoaging, wrinkles, scars, stretch marks, acne vulgaris and hair loss.
- Conditions
- Skin Texture Disorder, Photoaging, Wrinkle, Scar
- Trial name
- NCT06117293
- Testing
- Mosaic
- Where
- 3 sites in United States
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- CynosureLutronic
Atopic Dermatitis, Atopic
ATI-045 Versus Placebo in Patients With Moderate-to-Severe Atopic Dermatitis
This study evaluates ATI-045 versus placebo in patients with Moderate-to-Severe Atopic Dermatitis.
- Conditions
- Atopic Dermatitis, Atopic, Dermatitis, AD
- Trial name
- NCT07011706
- Testing
- ATI-045
- Where
- 60 sites in United States, Canada
- Volunteers
- 110 people
- Sponsor
- Aclaris Therapeutics, Inc.
Acne Vulgaris
A Comparative Study of the Tolerability of Two Combination Therapies for the Treatment of Acne
The purpose of this study is to compare the tolerability of topical combination therapies in the treatment of facial acne.
- Trial name
- NCT00887484
- Testing
- BENZOYL PEROXIDE/ CLINDAMYCIN, BENZOYL PEROXIDE/ ADAPALENE
- Where
- 4 sites in Argentina
- Volunteers
- 50 people
- Sponsor
- Stiefel, a GSK Company
Seborrheic Keratosis
Adaptive Design Study for Safety and Efficacy of Treatment Regimens With SM-020 in Subjects With Seborrheic Keratosis
This is a first-in-humans adaptive design open label trial to explore the safety and efficacy of SM-020. Multiple dosing cohorts will be enrolled.
- Trial name
- NCT05136144
- Testing
- SM-020
- Where
- El Salvador
- Volunteers
- 70 people, healthy volunteers welcome
- Sponsor
- DermBiont, Inc.
HER2-negative Breast Cancer
A Study to Investigate the Biological Effects of AZD9833 in Women With ER-positive, HER2 Negative Primary Breast Cancer
This is a randomised, open-label, parallel-group, pre-surgical study aimed to investigate the biological effects, safety, tolerability, and pharmacokinetics (PK) of different doses of oral AZD9833 in post-menopausal women with…
- Trial name
- SERENA-3 (NCT04588298)
- Testing
- AZD9833
- Where
- 12 sites in Georgia, Mexico and 1 more
- Volunteers
- 135 people
- Sponsor
- AstraZeneca
Breast Cancer
Re-Examination of Tumor Material and Re-Evaluation of Patient Data From Patients Treated With Neo-adjuvant Therapy
This is a prospective examination of ribonucleic acid (RNA) extracted from tumor material of breast cancer patients treated with a neo-adjuvant therapy.
- Trial name
- NCT02449993
- Testing
- MammaTyper™
- Volunteers
- 101 people
- Sponsor
- BioNTech Diagnostics GmbH
Advanced, Metastatic Breast Cancer
A Study to Investigate the Efficacy and Safety of Letrozole SIE Compared With Femara® (Both Combined With the CDK4/6 Inhibitor Ribociclib) in Postmenopausal Women With HR-Positive, HER2-Negative, Inoperable Locally Advanced or Metastatic Breast Cancer
The purpose of this study is to evaluate the efficacy and safety of Letrozole SIE (injectable) compared to Femara® (oral tablet), both given together with ribociclib, for the first-line treatment of postmenopausal women with…
- Trial name
- SIE-3 (NCT07340658)
- Volunteers
- 300 people
- Sponsor
- Rovi Pharmaceuticals Laboratories
Atopic Dermatitis
Jaktinib Hydrochloride Cream For Atopic Dermatitis
This study includes a dose escalation part and a dose extension part.
- Trial name
- NCT04435392
- Testing
- Jaktinib Hydrochloride Cream
- Where
- China
- Volunteers
- 107 people
- Sponsor
- Suzhou Zelgen Biopharmaceuticals Co.,Ltd
Skin Condition
Efficacy Testing of Collagen Elixir
To assess Isagenix-Collagen Elixir on skin condition improvement
- Trial name
- NCT04878536
- Testing
- Collagen drink, Blank
- Where
- Taiwan
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- TCI Co., Ltd.
Breast Cancer
Phase Ib Trial of LEE011 With Everolimus (RAD001) and Exemestane in the Treatment of Hormone Receptor Positive HER2 Negative Advanced Breast Cancer
Dose Escalation part of the study: To estimate the MTD(s) and/ or RP2D of LEE011 in combination with everolimus + exemestane, and LEE011 in combination with exemestane, and to characterize the safety and tolerability of the…
- Trial name
- NCT01857193
- Testing
- ribociclib (LEE011), Exemestane, Everolimus (RAD001)
- Where
- 13 sites in United States, Belgium and 3 more
- Volunteers
- 132 people
- Sponsor
- Novartis Pharmaceuticals
Breast Cancer
A Double-Blind, Comparative, Randomized Clinical Study of the Pharmacokinetics, Safety, and Immunogenicity of a Single Intravenous Infusion of BCD-178 or Perjeta® in Healthy Volunteers
This is a double-blind, comparative, randomized phase I study comparing pharmacokinetics, safety and immunogenicity profiles of a biosimilar pertuzumab (BCD-178) and Perjeta after a single intravenous infusion in healthy male…
- Trial name
- NCT05738993
- Testing
- BCD-178, Perjeta
- Where
- 2 sites in Russia
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Biocad
Metastatic Breast Cancer
A Study to Investigate the Effect of Food on the Bioavailability of Oral Paclitaxel Administered With Encequidar in Participants With Advanced Solid Tumors
The goal of this clinical trial is to learn about the effect of food on absorption of oral Paclitaxel when co- administered with Encequidar tablets in adult patients with tumours.
- Trial name
- NCT07580833
- Testing
- Oral Paclitaxel in combination with Encequidar tablet
- Volunteers
- 46 people
- Sponsor
- Health Hope Pharma
Breast Cancer
A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment.
The purpose of this study is to learn about the safety and effects of the study medicine PF-07248144 when given along with fulvestrant for the possible treatment of HR-positive, HER2-negative advanced or metastatic breast cancer.
- Trial name
- NCT07062965
- Testing
- PF-07248144, Fulvestrant, Everolimus
- Where
- 433 sites in United States, Argentina and 29 more
- Volunteers
- 400 people
- Sponsor
- Pfizer
Breast Cancer, Anemia
Treatment for Patients Suffering From Anemia Due to Chemotherapy
The purpose of this study is to validate a Patient Satisfaction Questionnaire for Anemia Treatment (PSQ-AT) in female breast cancer patients treated with darbepoetin alfa or recombinant human erythropoietin (rHuEPO) for anemia…
- Trial name
- NCT00120692
- Testing
- Darbepoetin Alfa, Recombinant Human Erythropoietin
- Sponsor
- Amgen
Cradle Cap, Infantile Seborrheic Dermatitis
Promiseb Topical Cream for Cradle Cap
The purpose of this study is to evaluate the efficacy and safety of Promiseb Topical Cream in cradle cap.
- Trial name
- NCT01214434
- Testing
- Promiseb Topical Cream, Bland emollient
- Where
- 4 sites in United States
- Volunteers
- 42 people
- Sponsor
- Promius Pharma, LLC
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.